Baxter’s Strategic Pivot: A Deep Dive into Its Financial Restructuring Plan
Published on 01/09/2026 at 18:11 | Redaktion boerse-global.de
Medical device giant Baxter International is implementing a comprehensive financial and operational strategy to counter persistent margin compression and manufacturing challenges. The company’s recent moves, including a drastic dividend cut and a new hospital partnership, have drawn mixed reactions from Wall Street, setting the stage for a critical investor update next week.
Market analysts presented contrasting perspectives on Baxter’s outlook this week. Barclays reaffirmed its Overweight rating on the stock but made a significant downward revision to its price target, lowering it from $36 to $30. Conversely, Goldman Sachs maintained a Neutral stance while nudging its target price slightly higher to $23. This split underscores the uncertainty surrounding the company’s Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
